

LIST OF TABLES

1.1 List of Tables

Table 1: Desired Characteristics of an MI Probe
Table 2: PET SWOT Analysis, 2013
Table 3: SPECT SWOT Analysis, 2013
Table 4: CT SWOT Analysis, 2013
Table 5: MRI SWOT Analysis, 2013
Table 6: Ultrasound Imaging SWOT Analysis, 2013
Table 7: Applications of MI
Table 8: Role of Biomarkers in Drug Development
Table 9: Molecular Imaging – Drivers and Barriers, 2013
Table 10: Small Molecules SWOT Analysis, 2013
Table 11: Agent Profile of [18F]FDG
Table 12: [18F]FDG SWOT Analysis, 2013
Table 13: Agent Profile of [18F]FLT
Table 14: [18F]FLT SWOT Analysis, 2013
Table 15: Agent Profile of [18F]FMISO
Table 16: [18F]FMISO SWOT Analysis, 2013
Table 17: Agent Profile of [18F]FAZA
Table 18: [18F]FAZA SWOT Analysis, 2013
Table 19: Agent Profile of [18F]FDOPA
Table 20: [18F]FDOPA SWOT Analysis, 2013
Table 21: Agent Profile of [18F]NaF
Table 22: [18F]NaF SWOT Analysis, 2013
Table 23: Agent Profile of [11C]Acetate
Table 24: [11C]Acetate SWOT Analysis, 2013
Table 25: Agent Profile of [11C]PiB
Table 26: [11C]PiB SWOT Analysis, 2013
Table 27: Peptides SWOT Analysis, 2013
Table 28: Nanoparticles SWOT Analysis, 2013
Table 29: Engineered Proteins SWOT Analysis, 2013
Table 30: Aptamers SWOT Analysis, 2013
Table 31: [18F]flurpiridaz SWOT Analysis, 2013
Table 32: NAV4694 SWOT Analysis, 2013
Table 33: [18F]flutemetamol SWOT Analysis, 2013
Table 34: [18F]florbetaben SWOT Analysis, 2013
Table 35: REDECTANE SWOT Analysis, 2013
Table 36: Navidea Biopharmaceuticals' Portfolio Assessment, 2013
Table 37: Navidea Biopharmaceuticals SWOT Analysis, 2013
Table 38: Lantheus Medical Imaging Portfolio Assessment, 2013
Table 39: Lantheus Medical Imaging SWOT Analysis, 2013
Table 40: Mallinckrodt Pharmaceuticals Portfolio Assessment, 2013
Table 41: Mallinckrodt Pharmaceuticals SWOT Analysis, 2013

Table 42: Avid Radiopharmaceuticals Portfolio Assessment, 2013
Table 43: Avid Radiopharmaceuticals SWOT Analysis, 2013
Table 44: Bracco Imaging Portfolio Assessment, 2013
Table 45: Bracco Imaging SWOT Analysis, 2013
Table 46: GE Healthcare Portfolio Assessment, 2013
Table 47: GE Healthcare SWOT Analysis, 2013
Table 48: Piramal Imaging Portfolio Assessment, 2013
Table 49: Piramal Imaging SWOT Analysis, 2013
Table 50: Siemens Portfolio Assessment, 2013
Table 51: Siemens SWOT Analysis, 2013
Table 52: Novelos Therapeutics Portfolio Assessment, 2013
Table 53: Novelos Therapeutics SWOT Analysis, 2013
Table 54: Affibody Portfolio Assessment, 2013
Table 55: Affibody SWOT Analysis, 2013
Table 56: Atreus Pharmaceuticals Portfolio Assessment, 2013
Table 57: Atreus Pharmaceuticals SWOT Analysis, 2013
Table 58: Kereos Portfolio Assessment, 2013
Table 59: Kereos SWOT Analysis, 2013
Table 60: Progenics Portfolio Assessment, 2013
Table 61: Progenics Pharmaceuticals SWOT Analysis, 2013
Table 62: FluoroPharma Medical Portfolio Assessment, 2013
Table 63: FluoroPharma Medical SWOT Analysis, 2013
Table 64: Willex Portfolio Assessment, 2013
Table 65: Willex SWOT Analysis, 2013
Table 66: Nordion SWOT Analysis, 2013
Table 67: Positron SWOT Analysis, 2013
Table 68: Cardinal Health SWOT Analysis, 2013
Table 69: AAA SWOT Analysis, 2013
Table 70: Other Companies in the MI Market, 2013
Table 71: Other Key Events in the Molecular Imaging Market

1.2 List of Figures

Figure 1: Components of an MI Probe
Figure 2: Imaging Modalities
Figure 3: Siemens Biograph TruePoint PET/CT Scanner
Figure 4: GE Healthcare's Discovery NM/CT 670 SPECT/CT Scanner
Figure 5: Philips' Brilliance iCT CT Scanner
Figure 6: Toshiba Medical Systems' Vantage Titan 3T MRI Scanner
Figure 7: Hitachi Preirus Ultrasound Scanner
Figure 8: Imaging Applications in Drug Discovery and Development
Figure 9: Categories of Imaging Probes
Figure 10: Molecular Structure of [18F]FDG
Figure 11: Whole-Body PET Scan Using [18F]FDG
Figure 12: Molecular Structure of [18F]FLT
Figure 13: PET Scan Using [18F]FLT
Figure 14: Molecular Structure of [18F]FMISO

- Figure 15: CT Scan (A), PET/CT Using [18F]FDG (B), and PET/CT Scan Using [18F]FMISO (C)
- Figure 16: Molecular Structure of [18F]FAZA
- Figure 17: [18F]FAZA-PET Scan
- Figure 18: Molecular Structure of [18F]FDOPA
- Figure 19: MRI Scan (Left) and [18F]FDOPA-PET Scan (Right)
- Figure 20: Molecular structure of NaF
- Figure 21: [18F]NaF-PET Bone Scan
- Figure 22: Molecular Structure of [11C]Acetate
- Figure 23: Comparison of Enhanced CT (A) with [18F]FDG-PET (B) and [11C]Acetate PET (C)
- Figure 24: Molecular Structure of [11C]PiB
- Figure 25: Comparison of [11C]PiB-PET Scans in Subjects with AD and Control Group
- Figure 26: Supply Chain for Medical Isotopes